Guggenheim Lowers Eli Lilly and Company (NYSE:LLY) Price Target to $1,161.00

Eli Lilly and Company (NYSE:LLY) had its price objective cut by analysts at Guggenheim from $1,163.00 to $1,161.00 in a note issued to investors on Tuesday, MarketBeat Ratings reports. The firm currently has a “buy” rating on the stock. Guggenheim’s price target points to a potential upside of 7.60% from the stock’s previous close.

Other research analysts have also recently issued research reports about the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Eli Lilly and Company in a report on Monday, December 1st. Daiwa Capital Markets set a $1,230.00 price objective on Eli Lilly and Company and gave the stock a “buy” rating in a report on Tuesday, December 16th. JPMorgan Chase & Co. lifted their price objective on Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a research note on Tuesday, November 18th. Loop Capital set a $950.00 target price on Eli Lilly and Company in a report on Monday, November 10th. Finally, The Goldman Sachs Group raised their price target on shares of Eli Lilly and Company from $951.00 to $1,145.00 and gave the company a “buy” rating in a report on Monday, December 15th. Four equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $1,174.61.

Eli Lilly and Company Stock Up 3.6%

LLY stock opened at $1,078.98 on Tuesday. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. The company’s 50 day simple moving average is $1,055.07 and its 200-day simple moving average is $876.57. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,133.95. The firm has a market capitalization of $1.02 trillion, a PE ratio of 52.79, a P/E/G ratio of 0.78 and a beta of 0.35.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The company had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same period in the prior year, the firm earned $1.18 EPS. The firm’s quarterly revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Institutional Trading of Eli Lilly and Company

Institutional investors and hedge funds have recently modified their holdings of the business. 10Elms LLP increased its position in Eli Lilly and Company by 33.3% in the 3rd quarter. 10Elms LLP now owns 40 shares of the company’s stock valued at $31,000 after acquiring an additional 10 shares during the period. M.E. Allison & CO. Inc. grew its stake in shares of Eli Lilly and Company by 0.7% in the fourth quarter. M.E. Allison & CO. Inc. now owns 1,477 shares of the company’s stock worth $1,587,000 after purchasing an additional 10 shares in the last quarter. Bridgewater Advisors Inc. increased its holdings in shares of Eli Lilly and Company by 0.3% during the third quarter. Bridgewater Advisors Inc. now owns 3,955 shares of the company’s stock valued at $3,018,000 after purchasing an additional 11 shares during the period. Manske Wealth Management raised its stake in shares of Eli Lilly and Company by 2.5% during the third quarter. Manske Wealth Management now owns 448 shares of the company’s stock valued at $342,000 after purchasing an additional 11 shares in the last quarter. Finally, Verus Wealth Management LLC raised its stake in shares of Eli Lilly and Company by 3.3% during the fourth quarter. Verus Wealth Management LLC now owns 343 shares of the company’s stock valued at $369,000 after purchasing an additional 11 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA grants Breakthrough Therapy designation to Lilly’s ovarian cancer candidate sofetabart (mipitecan), boosting the company’s oncology outlook and potential near-term regulatory value. Lilly’s sofetabart mipitecan receives U.S. FDA’s Breakthrough Therapy designation
• Positive Sentiment: SURMOUNT-REAL UK phase 4 update supports real‑world evidence for tirzepatide’s obesity benefit, which helps validate long-term market adoption and pricing power for Lilly’s GLP-1/dual-agonist franchise. Lilly’s SURMOUNT-REAL UK Trial: Real-World Test of Tirzepatide’s Obesity Upside
• Positive Sentiment: Retatrutide trial shows potential knee osteoarthritis relief tied to obesity treatment, suggesting additional indications and expanded patient populations for Lilly’s obesity pipeline. Eli Lilly’s Retatrutide Trial Links Obesity Treatment With Knee Osteoarthritis Relief Potential
• Positive Sentiment: Lilly launches a Phase 2 trial for a new oral drug targeting diabetic nerve pain, expanding non-GLP-1 growth avenues and diversifying future revenue streams. Eli Lilly Expands Its Pain Pipeline With New Phase 2 Trial in Diabetic Nerve Pain
• Neutral Sentiment: Lilly confirmed its Q4 2025 results and investor call for Feb. 4, giving the market a near-term event to reset guidance and expectations. Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement
• Neutral Sentiment: Analysts at Guggenheim trimmed LLY’s price target marginally (from $1,163 to $1,161) but kept a buy rating—little change to consensus upside but worth noting as analyst attention remains high. LLY: price target lowered by Guggenheim
• Neutral Sentiment: Market pieces and retrospectives highlight strong historical returns and positive analyst narratives (e.g., MarketBeat, Benzinga), supporting investor confidence but not constituting new catalysts. Here’s How Much You Would Have Made Owning Eli Lilly and Co Stock In The Last 5 Years
• Negative Sentiment: Commentary on Novo Nordisk’s new CEO and competitive strategy raises the profile of intense GLP-1 rivalry; investors may be watching pricing, market share, and promotional dynamics between LLY and Novo. Novo Nordisk: How Inspiring New CEO Will Take Fight To Key Rival Eli Lilly In 2026

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.